Kailera Therapeutics
Waltham
About Kailera Therapeutics
Kailera Therapeutics is a clinical-stage biopharmaceutical company developing therapeutic pipelines for obesity and type 2 diabetes. The pipeline includes injectable and oral peptides, such as GLP-1/GIP and GLP-1/GIP/Glucagon receptor agonists. Kailera Therapeutics licenses its therapies and conducts clinical trials focused on delivering treatment options for chronic weight management.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Total funding: $1.0B
- Funding stage: Early Stage Venture
- Last round: Series B (Oct 2025)
- Website: kailera.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/kailera-therapeutics-16462 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.